-

SLM INVESTOR REMINDER: SLM Corporation a/k/a Sallie Mae Investors Have Until February 17, 2026 To Seek Lead Plaintiff Role

NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your SLM Corporation a/k/a Sallie Mae (“SLM” or the “Company”) (NASDAQ:SLM) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost.

Investors have until February 17, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions.

[CONTACT THE FIRM IF YOU SUFFERED A LOSS]

What Is The Lawsuit About?

The lawsuit has been filed on behalf of investors who purchased securities during the period of July 25, 2025 through August 14, 2025, inclusive (“the Class Period”). The lawsuit alleges SLM made false and/or misleading statements and/or failed to disclose that: (i) SLM was experiencing a significant increase in early stage delinquencies and (ii) accordingly, SLM overstated the effectiveness of SLM's loss mitigation and/or loan modification programs, as well as the overall stability of the Company's PEL delinquency rates.

On August 14, 2025, investment bank TD Cowen issued a report addressing SLM, flagging that, “overall, July [2025] delinquencies were up 49 bp m/m, higher (worse) than the seasonal (+10 bps) performance for July, driven by a 45 bps increase in early stage delinquencies.” Notably, TD Cowen’s findings directly contradicted assurances made late in the month of July 2025 that SLM were observing delinquency rates that “really are following the normal seasonal trends we would expect in the business.” On this news, the price of SLM shares declined by $2.67 per share, or approximately 8.1%, from $32.99 per share on August 14, 2025 to close at $30.32 on August 15, 2025.

[CLICK HERE TO LEARN MORE ABOUT THE CLASS ACTION]

What Should I Do?

If you purchased or otherwise acquired SLM securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[WHAT IS A SECURITIES CLASS ACTION?]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
investigations@kmllp.com

Kirby McInerney LLP

NASDAQ:SLM

Release Versions

Contacts

Kirby McInerney LLP
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
investigations@kmllp.com

More News From Kirby McInerney LLP

GE HEALTHCARE TECHNOLOGIES INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (NASDAQ:GEHC). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On April 29, 2026, GE HealthCare reported its financial results for the first quar...

ERASCA, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ:ERAS). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On April 28, 2026, Erasca disclosed receipt of a letter from Revolution Medicines alleging that Erasca’s ERA...

QIAGEN N.V. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Qiagen N.V. (“Qiagen” or the “Company”) (NYSE:QGEN). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On February 5, 2026, Qiagen released fourth quarter 2025 earnings and stated that QuantiFERON would accelerate...
Back to Newsroom